Scientific Overview

CD1d/NKT-binding glycolipids as an adjuvant for T cell-based HIV and malaria vaccines
The eradication of global pathogens responsible for endemic and pandemic diseases hinges upon the development of effective vaccines. This is certainly the case for HIV and malaria. However, our inability to elicit “strong and long-lasting” protective T cell responses, particularly CD8+ T cell responses, has been a major obstacle to successful vaccine development. Accordingly, adjuvant technologies will likely be critical not only to overcome pre-existing immunity to viral vaccine vectors but also to further enhance vaccine immunogenicity. Our previous studies have demonstrated that a CD1d molecule-binding, natural killer T (NKT) cell ligand, alpha-galactosylceramide (alpha-GalCer), can enhance protective CD8+ T cell responses elicited by HIV and malaria vaccines, including a DNA vaccine encoding HIV antigens and a recombinant adenovirus expressing a malarial antigen. In collaboration with two eminent chemistry groups directed by Dr. Chi-Huey Wong and Dr. Richard Franck, we have successfully identified several alpha-GalCer analogues that act as an NKT cell ligand. These include a synthetic C-glycoside analogue, alpha-C-GalCer (JEM in 2003 and PNAS in 2005), a sulfatide analogue, 3-O-sulfo-GalCer (PNAS in 2005), two bacterial glycosphingolipids, GSL-1A and GSL-1B, derived from Sphingomonas (Nature in 2005), and a diacylglycerol from Borrelia burgdorferi (Nature Immunology in 2006). Our most recent results indicate that introduction of a phenyl group at the end of eight fatty acid carbon chain yielded activities superior to alpha-GalCer (JACS in 2006). Thus, concrete clues on the structure-activity-relationship (SAR) are emerging from our preliminary studies on an initial library screening of glycolipids. We are continuing to screen a focused library of several hundreds alpha-GalCer analogues that we are generating, and selecting a smaller panel of candidate glycolipids based on their in vitro cytokine production profiles upon cultivation with murine and human NKT cells. We are also determining the in vivo cytokine production profiles elicited by the selected glycolipids upon administering them into mice. These in vitro and in vivo screening process will lead us to choose about a handful of promising candidate glycolipids that would display strong Th1-biased, Th2-biased, or bipolar activities. These glycolipids having a distinct biological activity will present us an opportunity to determine the means by which glycolipids elicit Th1 versus Th2 cytokine secretion, in collaboration with Dr. Mitchell Kronenberg at La Jolla Institute of Allergy & Immunology. Ultimately, we plan to determine the magnitude of adjuvant effect that each of these newly identified glycolipids contributes to the immunogenicity of HIV and malaria vaccines in a mouse model.

Identification of novel synthetic analogues of alpha-GalCer, as an immuno-enhancing molecule for vaccines against HIV and malaria
Although many attempts have been made to develop HIV and malaria vaccines, they have been unsuccessful to date. The main reason for this failure is that the vaccines have not been immunologically strong, that is immunogenic enough to prevent the infection and/or to prolong anti-HIV/malaria immunity. Therefore, it is essential to develop a compound that can significantly enhance the immunogenicity of HIV/malaria vaccines. Our previous studies have demonstrated that a CD1d molecule-binding, natural killer T (NKT) cell ligand, alpha-galactosylceramide (alpha-GalCer), can enhance the immunogenicity of vaccines against HIV and malaria in a mouse model. Most recently, we have discovered that modification of alpha-GalCer can results in compounds with stronger biological activity (NKT cell stimulating activity) than alpha-GalCer. Therefore, our main goal is to determine whether some of the alpha-GalCer analogues could display a far superior immuno-enhancing activity, thereby greatly improving the efficacy of vaccines against HIV and malaria.

NAME: Moriya Tsuji, M.D., Ph.D.

ADDRESS:

HIV and Malaria Vaccine Program Aaron Diamond AIDS Research Center The Rockefeller University 455 First Avenue New York, NY 10016

TELEPHONE: 212-448-5021
TELEFAX: 212-725-1126

E-MAIL: mtsuji@adarc.org

EDUCATION

1983	M.D.   The Jikei University School of Medicine, Tokyo, Japan
1987	Ph.D. University of Tokyo, Faculty of Medicine, Tokyo, Japan (Mentor – Prof. Tomio Tada)

LICENSURE AND CERTIFICATION

1983	National Board of Medical Examiners of Japan

ACADEMIC APPOINTMENTS

1990 – 1991	Instructor, Department of Medical and Molecular Parasitology, NYU School of Medicine, New York
1991 - 1998	Assistant Professor, Department of Medical and Molecular Parasitology, NYU School of Medicine, New York
1998 - 2005	Associate Professor (with tenure), Department of Medical and Molecular Parasitology, NYU School of Medicine, New York
2003 - 2004	Visiting Investigator (sabbatical), Aaron Diamond AIDS Research Center, New York
2004 -	Aaron Diamond Associate Professor, The Rockefeller University, Staff Investigator, HIV and Malaria Vaccine Program, Aaron Diamond AIDS Research Center
2006 -	Adjunct Associate Professor, Department of Medical Parasitology, NYU School of Medicine, New York

AWARDS AND HONORS

1983 - 1987	Japan Scholarship Society Award
1992 - 1993	American Cancer Society Institutional Award
1993 - 1994	New York University Whitehead Presidential Award
1994	Arthritis Foundation Award
1996 - 1998	American Lung Association of New York Research Award
1997 - 2002	NIH FIRST Award
1999 - 2003	NIH Independent Scientist Award
2009 - 2010	Gates Grand Challenges Explorations Round 3

MAJOR COMMITTEE ASSIGNMENTS

1998 - 2003	Admission Committee member on the Medical Scientist Training Program (M.D.-Ph.D. Program), New York University School of Medicine, New York
2004 - 2005	Faculty Promotion Committee, Department of Medical and Molecular Parasitology, New York University School of Medicine, New York
2005	Mentoring Committee for Junior Faculty of Medicine at NYUSM (advisors: Moriya Tsuji, Dan Littman, Bruce Cronstein)
2005	Ad Hoc Committee member on Tenure, NYUSM. New York

THESIS COMMITTEES

1997	Elaine Rodrigues, Ph.D. at Federal University of Sao Paulo (advisor: Moriya Tsuji)
1998	Daniel Nam, M.D., Ph.D. at NYU School of Medicine (advisor: David Ho)
2002	Wenyong Zhang, M.D., Ph.D. at the Rockefeller University (advisor: David Ho)
2004	John Schmieg, M.D., Ph.D. at NYU School of Medicine (advisor: Moriya Tsuji)
2008	Olga Ophorst, PhD. at University of Amsterdam (advisor: Jaap Goudsmit)
2008	Halonna Kelly, PhD. at NYU School of Medicine (advisor: Jaap Goudsmit)
2008	Tal Hasson, Ph.D. at Hunter college of CUNY (advisor: Akira Kawamura)

MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES

1993	American Association for the Advancement of Science
1993	American Association of Immunologists
1996 - 2001	American Society of Tropical Medicine and Hygiene
1997	International Society for Vaccines
1998	Scientific Co-Chairman, 9th International Congress of Parasitology, Chiba, Japan; August 24-28
1999	Scientific Co-Chairman, 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC; November 28 – December 2
2007	Member, Faculty of 1000 Biology, Immunology Section
2008	Session Chair, Keystone Symposium - NK and NKT cell Biology, Keystone, Colorado, February 24-29
2008	A member of Technical Advisory Group (TAG) for malaria vaccine development, The PATH Malaria Vaccine Initiative (MVI), Bethesda, MD, May 1
2008	A member of Technical Advisory Group (TAG) for malaria vaccine development. The PATH Malaria Vaccine Initiative (MVI), Bethesda, MD, October 29
2008	Panel member, Vaccine Science Portfolio Advisory Council (VSPAC) of the PATH Malaria Vaccine Initiative (MVI), Bethesda, MD
2009	Chairman, 1st Malaria Vaccine Workshop organized by Otsuki Pharmaceutical Co., Ltd., Tokyo, Japan
2010	Panel member, Malaria Vaccine Consultation Group (MVCG) of NIAID, NIH
2011, June	Scientific Advisory Group (SAG) member for the NIH/NIAID site visit to the International Center for Excellence in Malaria Research (ICEMR) in Cali, Colombia

GRANT REVIEW ASSIGNMENT

1999	Office of Naval Research, Medical Science and Technology Division
2000	Member of the Board of Experts, Italian Ministry for University and Research
2000 – 2003	Department of Defense, Military Infectious Diseases Research Program, American Institute of Biological Sciences – Panel member
2001	Malaria Vaccine Initiative, PATH (Gates) Foundation (Ad Hoc)
2002, Apr	NIH Study Section, AIDS & Related Research IRG
2003	The Welcome Trust, UK
2003	The French Microbiology Program, The French Ministry of Research and New Technologies
2003, Oct	NIH Study Section, Special Emphasis Panel ZRG1 SSSF 01
2004	Member of the Board of Experts, Committee for Research Evaluation (CIVR), Italy
2004 – 2008	NIH Study Section Roster Member, Immunity and Host Defense (IHD)
2005, Jun	NIH Study Section, Special Emphasis Panel ZRG1, Infection, Accessory Cells and Immunity (IMM-J)
2006, Jun	NIH Study Section, Innate Immunity and Inflammation (III)
2007, Jul	NIH Study Section, ZAI1 BLG-IS11, T-cell Immunology
2008, Jan	United States-Israel Binational Science Foundation (BSF)
2008, May	NIDA Avant-garde Award, ADA1 NXR-B1, HIV Immunology
2009, Mar	NIH Study Section, ZRG1 IDM-P (50), International Research in Infectious Diseases
2009, Apr	NIDA Avant-Garde Award, ZDA1 NXR-B1, HIV Immunology
2009, Jun	HIV Study Section, Challenge Grants, ZRG1 IMM-E & IDM-C
2009, Sept	NIH Study Section, SBIR/STTR, CSR ZRG1 IMM-G (13) B & (14) B
2009, Oct	NIH Study Section, SEP ZRG1 IMM-H02
2010, Jan	NIH Study Section, SEP ZAI1 AWA-M (M1)
2010, Feb	NIH Study Section, Immunity and Host Defense (IHD)
2010, Jun	NIH Study Section, SEP ZAG1 IMM-E(02)

JOURNAL REVIEW ASSIGNMENT

1991	Journal of Immunological Methods
1993	American Journal of Tropical Medicine and Hygiene
1994	Journal of Infectious Diseases
1994	Parasitology Today
1995	Journal of Immunology
1996	Infection and Immunity
1997	Vaccine
1999	Experimental Parasitology
2000	International Immunology
2002	Journal of Experimental Medicine
2002	Blood
2002	Journal of Clinical Investigation
2003	Journal of AIDS
2004	Annual Review of Immunology
2005	Microbes and Infection
2006	European Journal of Immunology
2006	PLoS ONE
2008	BMC Immunology
2010	Bioorganic & Medicinal Chemistry
2010	Clinical Immunology
Editorial Board
2007-	Virology: Research and Treatment
2009-	Journal of AIDS
2010-	Biomolecules
2011-	PLoS ONE

TEACHING EXPERIENCE

1992 - 2001	Instructor in Parasitology course for medical students at New York University
1993 - 1998	Lectures on Immunology for graduate students at New York University
1994	Lectures on Immunology for undergraduate students at New York University
1997	Lectures on Immunology for graduate students at Federal University of Sao Paulo, Sao Paulo, Brazil
1998 - 2000	Lectures on Immunology for medical students at University of Mali, Bamako, Mali

SEMINAR ORGANIZER

1993 - 1994	Immunology Club Seminar Series, Dean’s Office, NYU School of Medicine
1997 - 1998	Parasitology Seminar Series, Department of Medical and Molecular
2000 - 2001	Parasitology, NYU School of Medicine

MAJOR RESEARCH INTERESTS

Development of T cell-based vaccines against malaria

Discovery of new adjuvants for vaccines

Mechanisms of protective cell-mediated immunity against malaria and HIV

BIBLIOGRAPHY - JOURNALS

• Tsuji M, Yagi J, Abe R, Asano Y, Tada T. 1987. Shared idiotopes between anti-class II monoclonal antibodies and major histocompatibility complex restriction site of T cells. Eur. J. Immunol. 117: 675-81.
• Tsuji M, Romero P, Nussenzweig RS, Zavala F. 1990. CD4+ cytolytic T cell clone confers protection against murine malaria. J. Exp. Med. 172:1353-7.
• Tsuji M. 1990. The development of malaria vaccine: Induction of T cells is the main stream of sporozoite vaccine develoment. Prog. Med. 152: 160. In Japanese. Review.
• Tsuji M. 1991. Immunity to malaria: Sporozoite vaccine development. Inf. Infl. Immun. 21: 149-56. In Japanese. Review.
• Tsuji M, Corradin G, Zavala F. 1992. Monoclonal antibodies recognize a processing dependent epitope present in the mature CS protein of various plasmodial species. Parasite Immunol. 14: 457-69.
• Feng Z., Hoffman RN, Nussenzweig RS, Tsuji M, Fujioka H, Aikawa M, Lensen THW, Ponnudurai T, Pologe LG. 1993. Pfs 2400 can mediate antibody-dependent malaria transmission inhibition and may be the Pasmodium falciparum 11.1 gene product. J. Exp. Med. 177: 273-81.
• Tsuji M, Mombaerts P, Lefrancois L, Nussenzweig RS, Zavala F Tonegawa S. 1994. γ/δ Tcells contribute to immunity against the liver stages of malaria in α/β T cell-deficient mice. Proc. Natl. Acad. Sci. USA. 91: 345-9.
• Tsuji M, Mattei D, Nussenzweig RS, Eichinger D, Zavala F. 1994. Demonstration of heat-shock protein 70 in the sporozoite stage of malaria parasites. Parasitol. Res. 80: 16-21.
• Tsuji M, Miyahira Y, Nussenzweig RS, Aguet M and Zavala F. 1995. Development of anti-malaria immunity in mice lacking interferon- receptor. J. Immunol. 154: 5338-44.
• Reardon CL, Heyborne K, Tsuji M, Zavala, F, Tigelaar, RE, O’Brien RL Born WK. 1995. Murine epidermal Vγ5/Vδ1-TCR+ T cells respond to B cell lines and lipopolysaccharides. J. Invest. Dermatology 105: 58-61.
• Tsuji M. 1996. Immunity to malaria: Protective immune mechanisms mediated by T cells. Inf. Infl. Immun. 26: 2-9. In Japanese. Review.
• Tsuji M, Eyster C, O’Brien R, Born WK, Bapna M, Reichel M, Nussenzweig RS, Zavala F. 1996. Phenotypic and functional properties of murine γ/δ T cell clones derived from malaria immunized, αβ T cell-deficient mice. Int. Immunol. 8: 359-66.
• Briones M, Tsuji M, Nussenzweig V. 1996. Differential infectivity of Plasmodium berghei and P. yoelii in vivo is established primarily after sporozoite invasion of liver cells. Mol. Bio. Parasitol. 77: 7-17.
• Takita-Sonoda Y, Tsuji M, Kamboj K, Nussenzweig RS, Clavijo P, Zavala F. 1996. Plasmodium yoelii: Peptide immunization induces protective CD4+ T cells against a previously unrecognized cryptic epitope of the circumsporozoite protein. Exp. Parasitol. 84: 223-30.
• Murata K, Garcia-Sastre A, Tsuji M, Rodrigues M, Rodriguez D, Rodriguez JR, Nussenzweig, RS, Palese P, Esteban M, Zavala F. 1996. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol. 173: 96-107.
• Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M. 1997. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J. Immunol. 158: 1268-74.
• Miyahira Y, Garcia-Sastre A, Rodriguez JR, Rodriguez D, Murata K, Tsuji M, Esteban M, Palese P, Zavala F Nussenzweig, R.S. 1998. Recombinant viruses expressing a human malaria antigen elicited protective cellular and humoral responses in mice. Proc. Natl. Acad. Sci. USA. 95: 3954-9.
• Tsuji M, Bergmann CC, Takita-Sonoda Y, Murata, K, Rodrigues EG, Nussenzweig RS, Zavala F. 1998. Recombinant Sindbis viruses expressing a cytotoxic T lymphocyte epitope of a malaria parasite or of an influenza virus elicit protection against the corresponding pathogen in mice. J. Virol. 72: 6907-10.
• Rodrigues EG, Zavala F, Nussenzweig RS, Wilson JM, Tsuji M. 1998. Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 16: 1812-17.
• Tsuji M. 1998. Immunity and parasitic diseases. Today’s Therapy 21: 1-2. In Japanese. Review.
• Fernandez JA, Zavala F, Tsuji M. 1999. Phenotypic and functional characterization of CD8+ T cell clones specific for a mouse cytomegalovirus epitope. Virology 155: 40-49.
• Yoneto T, Yoshimoto T, Wang C-R, Takahama Y, Tsuji M, Waki S. Nariuchi H. 1999. IFN γ but not NO nor NK cells are critical for the protective immunity to infection with blood stage Plasmodium berghei XAT. Inf. Immun. 67: 2349-56.
• Tsuji, M. 1999. Current status of malaria vaccine development. Prog. Med. 191: 88-92. In Japanese. Review.
• de Oliveira CI, Wunderlich G, Levitus G, Soares IS. Rodrigues MM, Tsuji M, del Portillo HA. 1999. Immunogenic properties of the merozoite surface proteint 1 gene of Plasmodium vivax. Vaccine 17: 2959-2968.
• Rodrigues EG, Claassen J, Lee S, Wilson JM, Nussenzweig RS, Tsuji M. 2000. Interferon-gamma Independent CD8+ T cell-mediated protective anti-malaria immunity induced by recombinant adenovirus. Parasite Immunol. 22: 157-160.
• McKenna KC, Tsuji M, Sarzotti M, Sacci JBJr, Witney AA, Azad A. 2000. gamma/delta T cells are a component of early immunity against preerythrocytic malaria parasites. Inf. Immun. 68: 2224-2230.
• Molano A, Chiu Y-H, Nosseir S, Bendelac A, Tsuji M. 2000. Cutting Edge: The IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: Exploring the role of GPIs in NKT cell activation and antimalarial responses. J. Immunol. 164: 5005-5009.
• Nagaoka H, Gonzalez-Aseguinolaza G, Tsuji M, Nussenzweig M. 2000. Immunization and infection change the number of RAG expressing B cells in the periphery by altering immature lymphocyte production. J. Exp. Med. 191: 2113-2120.
• Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, Bruna-Romero O, Nakayama T, Taniguchi M, Bendelac A, Van Kaer L, Koezuka Y, Tsuji, M. 2000. α-GalCer-activated Vα14 natural killer T cells mediate protection against murine malaria. Proc. Natl. Acad. Sci. USA. 97: 8461-8466.
• Cady CT, Lahn M, Vollmer M, Tsuji M, Seong JS, Reardon CL, O’Brien RL, Born W. 2000. Innate response of murine γδ T cells to the synthetic polypeptide, poly Glu50Tyr50. J. Immunol. 165: 1790-1798.
• Pasquetto V, Guidotti LG, Kakimi K, Tsuji M, Chisari FV. 2000. Host-virus interactions during malaria infection in hepatitis B virus transgenic mice. J. Exp. Med. 192: 529-536.
• Fernandez JA, Rodrigues EG, Tsuji M. 2000. Multifactorial protective mechanisms to limit viral replication in the lung of mice during primary murine cytomegalovirus infection. Viral. Immunol. 13: 287-295.
• Rodrigues EG, Tsuji M. 2000. Malaria Vaccine Development: Various immunization regimens for efficient induction of protective anti-malaria immunity. Science and Culture 52: 288-304. Review.
• Tsuji M, Rodrigues EG, Nussenzweig RS. 2001. Progress towards a malaria vaccine: Efficient induction of anti-malaria immunity. Biol. Chemistry 382: 553-570. Review.
• Bruna-Romero O. Hafalla JCR, Gonzalez-Aseguinolaza G, Sano G-I, Tsuji M, Zavala F. 2001. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int. J. Parasitol. 31: 1499-1502.
• Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla JC, Tsuji M. Nussenzweig RS. 2001. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. USA. 98: 11491-11496.
• Tsuji M, Zavala F. 2001. Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites. Mol. Immunol. 38; 433-442. Review.
• Gonzalez-Aseguinolaza G, Van Kear L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M. 2002. The natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195: 617-624.
• Gonzalez-Aseguinolaza G, Schmieg J, Berraondo P, Ochoa L, Tsuji M. 2002. The involvement of CD1d-restricted NKT cells in infectious processes. Revision 21: 145-155. Review.
• Tsuji, M. 2002. A novel immune mechanism against malaria: The involvement of NKT cells. Inf. Infl. Immun. 32: 2-9. In Japanese. Review.
• Tsuji M, Zavala F. 2003. T cells as mediators of protective immunity against malaria liver stages. Trends in Parasitol. 19: 88-93. Review.
• Bruna-Romero O, Schmieg J, Del Val M, Buschle M, Tsuji M. 2003. The dendritic cell-specific chemokine DC-CK1 enhances protective cell-mediated immunity to murine malaria. J. Immunol. 170: 3195-3203.
• Schmieg J, Gonzalez-Aseguinolaza G, Tsuji M. 2003. The role of natural killer T cells and other T cell subsets against infection by liver stages of malaria parasites. Microbes and Inf. 5: 499-506. Review.
• Schmieg J, Yang G, Franck RW, Tsuji M. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 198: 1631-1641.
• Yang G, Schmieg J, Tsuji M, Franck RW. 2004. The C-glycoside analogue of the immunostimulant alpha-galactosylceramide (KRN7000): synthesis and striking enhancement of activity. Angew. Chem. Int. Ed. Eng. 19: 3818-3822.
• Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT. 2004. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine 22: 3575-3584.
• Chen G, Schmieg J, Tsuji M, Franck RW. 2004. Efficient Synthesis of alpha-C-Galactosyl Ceramide Immunostimulants: Use of Ethylene-Promoted Olefin Cross-Metathesis. Org. Lett. 6: 4077-4080.
• Schmieg J, Yang G, Franck RW, Van Rooijen N, Tsuji M. 2005. Glycolipid-presentation to natural killer T cells differs in an organ-dependent fashion. Proc. Natl. Acad. Sci. USA. 102: 1127-1132.
• Wu D, Xing G-w, Poles MA, Horowitz A, Kinjo Y, Sullivan B, Bodmer-Narkevitch V, Plettenburg O, Kronenberg M, Tsuji M, Ho DD, Wong C-H. 2005. Novel bacterial glycolipids and analogues as antigens for CD1d-restricted NKT cells. Proc. Natl. Acad. Sci. USA. 102: 1352 -1356.
• Xing GW, Wu D, Poles MA, Horowitz A, Tsuji M, Ho DD, Wong CH. 2005 Synthesis and human NKT cell stimulating properties of 3-O-sulfo-alpha/beta-galactosylceramides. Bioorg. Med. Chem. 13:2907-2916.
• Kinjo Y, Wu D, Kim G, Xing G-w, Poles MA, Ho DD, Tsuji M, Kawahara K, Wong C-H, Kronenberg M. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520 - 525.
• Kennan RP, Machado FS, Lee SC, Desruisseaux MS, Wittner M, Tsuji M, Tanowitz, HB. 2005. Reduced cerebral blood flow and N-acetyl aspartate in a murine model of cerebral malaria. Parasitol. Res. 96: 302 - 307.
• Ophorst OJAE, Radosevic K, Havenga MJE, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M. 2006. Recombinant human adenovirus serotype 35-based malaria vaccine: Immunogenicity and protection against Plasmodium yoelii in mice. Infect. Immun. 74: 313-320.
• Machado F, Desruisseau MS, Nagajyoshi, Kennan RP, Hetherington HP, Wittner M, Weiss LM, Lee SC, Scherer PE, Tsuji M, Tanowitz HB. 2006. Endothelin in a Murine Model of Cerebral Malaria. Exp. Biol. Med. 231: 1176-1181.
• Chen G, Chien M, Tsuji M, Franck RW. 2006. E and Z αC-Galactosylceramides via Julia-Lythgoe-Kocienski Chemistry: A Test of the Receptor Binding Model for Glycolipid Immunostimulants. Chem. Bio. Chem. 7: 1017-1022.
• Fujio M, Wu D, Garcia-Navarro R, Ho D.D, Tsuji M, Wong C-H. 2006. Structure-Based Discovery of Glycolipids for CD1d-mediated NKT cell activation: Tuning the Adjuvant versus Immunosuppression Activity. J. Am. Chem. Soc. 128: 9022-9023.
• Tsuji M. 2006. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell. Mol. Life Sci. 63:1889-1898. Review.
• Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Franck RW, Tsuji M, Steinman RM. 2006. The glycolipid α-C-GalCer is a distinct inducer of dendritic cell maturation and both innate and adaptive T cell immunity in mice. Proc.Natl.Acad.Sci. USA. 103:11252-11257.
• Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia M, Zajonc DM, Ben-Menachem G, Ainge GD, Painter GF, Khurana A, Hoebe K, Behar SM, Beutler B, Wilson IA, Tsuji M, Sellati TJ, Wong C-H, Kronenberg M. 2006. NKT cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7: 978-986.
• Franck RW, Tsuji M. 2006. α-C-Galactosylceramides: Synthesis and Immunology. Acc. Chem. Res. 39: 692-701. Review.
• Teng MWL, Westwood JA, Darcy PK, Sharkey J, Chen G, Tsuji M, Franck RW, Porcelli SA, Besra G, Godfrey DI, Takeda K, Yagita H, Kershaw MH, Smyth MJ. 2007. Combined NKT cell-based immunotherapy eradicates established tumors in mice. Cancer Res. 67: 7495-7504
• Coppieters K, Van Beneden K, Jacques P, Dewint P, Vervloet A, Vander Cruyssen B, Van Calenbergh S, Chen G, Franck R.W, Heremans H, De Clercq B, Verbruggen G, Deforce D, Matthys P, Tsuji M, Rottiers P, Elewaut D. 2007. Long-term IFN-g Dependent Efficacy of Activated Va14i Natural Killer T cells in the Prevention of Collagen-Induced Arthritis. J. Immunol. 179: 2300-2309.
• Vasan S, Poles MA, Horowitz A, Siladji EE, Markowitz M, Tsuji M. 2007. Percentage and function of NKT cells, a potential anti-HIV effector cell, are preserved by beginning HAART during acute and early HIV-1 Infection. Int. Immunol. 19: 943-951.
• Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, Gurner D, Gardiner D, Basu S, Ho DD, Tsuji M, 2008. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine. 2008 Mar 28;26(15):1807-16.
• Desruisseaux MS, Gulinello M, Smith DN, Lee SC, Tsuji M, Weiss LM, Spray DC, Tanowitz HB. 2008. Cognitive dysfunction in mice infected with Plasmodium berghei strain ANKA. J Infect Dis. 2008 Jun 1;197(11):1621-7.
• Liang PH, Imamura M, Li X, Wu D, Fujio M, Guy RT, Wu BC, Tsuji M, Wong CH. 2008. Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production. J Am Chem Soc. 2008 Sep 17;130(37):12348-54.
• Grajewski RS, Agarwal RK, Kronenberg M, Sidobre S, Su SB, Silver PB, Tsuji M, Franck RW, Lawton AP, Chan C-C, Caspi RR. 2008. Activation of iNKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-γ production and dampening of the adaptive Th1 and Th17 responses. J Immunol. 2008 Oct 1;181(7):4791-7.
• Shiratsuchi T, Schneck J, Kawamura A, Tsuji M. 2009. Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J Immunol Methods. 2009 Jun 30;345(1-2):49-59.
• Kopecky-Bromberg SA, Fraser KA, Pica N, Carnero E, Moran TM, Franck RW, Tsuji M, Palese P. 2009. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine. 2009 Jun 8;27(28):3766-74.
• Li X, Chen G, Garcia-Navarro R, Franck RW, Tsuji M. 2009 Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells. Immunology. 2009 Jun;127(2):216-225.
• Li X, Shiratsuchi T, Chen G, Dellabona P, Casorati G, Franck RW, Tsuji M. 2009. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells. J Immunol. 2009 Oct 1;183(7):4415-21.
• Horowitz A, Li X, Poles MA, Tsuji M. 2009. Use of immobilized HLA-A2:Ig dimeric proteins to determine the level of epitope-specific, HLA-restricted CD8(+) T-cell response. Scand J Immunol. 2009 Nov;70(5):415-22
• Schmieg J, Yang G, Franck RW,Tsuji M. 2010. A multifactorial mechanism in the superior anti-malarial activity of a-C-GalCar J. Biomed Biotech. 2010:283612.
• Vasan S, Tsuji M. 2009. Friend-Foe & Predator-Prey Relationship: the role of NKT cells in Malaria and HIV infection and immunity. Semin Immunol. 2010 Apr;22(2):87-96.
• Tsuji M. 2009. Re-evaluating the role of T cells for the development of T cell-based malaria vaccine. Exp. Parasitol. Invited Review.
• Shiratsuchi T, Kraus A, Worgall S, Tsuji M. 2010. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest. 2010 Oct;120(10):3688-701.
• Li X, Fujio M, Imamura M, Wu D, Vasan S, Wong CH, Ho DD, Tsuji M. 2010. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci, 20;107(29):13010-5.
• Li X, Shiratsuchi T, Chen G, Franck RW, Tsuji M. 2009. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine iNKT cells. J. Immunol. 183: 4415-4421.
• Horowitz A, Li X, Poles MA, Tsuji M. 2009. Quantifying cytokine production by epitope-specific, HLA-restricted CD8+ T cells after stimulation by immobilized HLA-A2:Ig dimeric proteins. Scan. J. Immunol. 70: 415-422.
• Sullivan BA, Nagarajan NA, Wingender G, Wang J, Scott I, Tsuji M. Franck RW, Porcelli SA, Zajonc DM, Kronenberg M. 2010. Mechanisms for Glycolipid Antigen-Driven Cytokine Polarization by V{alpha}14i NKT Cells. J. Immunol. 184: 141-153.
• Vasan S, Tsuji M. 2010. A double-edged sword: The Role of NKT cells in Malaria and HIV Infection and Immunity. Seminar Immunol. Review. 22: 87-96.
• Schmieg J, Yang G, Franck RW, Tsuji M. 2010. A multifactorial mechanism in the superior anti-malarial activity of a-C-GalCer. J. Biomed. Biotech. 2010: 283612: 1-11.
• Stock P, Lombardi V, Yang W, Sullivan BA, Li X, Shiratsuchi T, Hnatiuk NE Howell AR, Yu KOA, Porcelli SA, Tsuji M, Kronenberg M, Wilson SB, Akbari O. 2010. A CD1d-dependent antagonist inhibits the activation of iNKT cells and prevents development of allergen-induced airway hyperreactivity. J. Immunol. 184: 2107-15.
• Tsuji M. 2010. Re-evaluating the role of T cells for the development of T cell-based, malaria vaccine. Exp. Parasitol. Review.
• Li X, Fujio M, Imamura M, Wu D, Vasan S, Wong CH, Ho DD, Tsuji M. 2010. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci, 20;107(29):13010-5.
• Shiratsuchi T, Rai U, Kraus A, Worgall S, Tsuji M. 2010. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents pre-existing immunity to adenovirus in mice. J. Clin. Invest. 120(10):3688-701.
• Renukaradhya GJ, Manickam C, Khatri M, Rauf A, Li X, Tsuji M. Rajashekara G, Dwivedi V. 2010. Functional Invariant NKT Cells in Pig Lungs Regulate the Airway Hyperreactivity: A Potential Animal Model. J. Clin Immunol. 31(2):228-39.
• Padte NN, Li X, Tsuji M, Vasan S. 2010. Clinical Development of a Novel CD1d-binding NKT Cell Ligand as a Vaccine Adjuvant. Clin Immunol. 140(2):142-51.
• Mishra S, Rai U, Shiratsuchi T, Li X, Vanloubbeeck Y, Cohen J, Nussenzweig RS, Winzeler EA, Tsuji M,Nussenzweig V. 2011. Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites. Vaccine. 29(43):7335-42.
• Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, Li Y, Imamura M, Kaneko Y, Okawara A, Miyazaki Y, Gómez-Velasco A, Rogers P, Dahesh S, Uchiyama S, Khurana A, Kawahara K, Yesilkaya H, Andrew PW, Wong CH, Kawakami K, Nizet V, Besra GS,Tsuji M, Zajonc DM, Kronenberg M. 2011. Invariant NKT cells recognize glycolipids from pathogenic gram-positive bacteria. Nat Immunol. 2011 Sep 4;12(10):966-74.
• Avci FY, Li X, Tsuji M,Kasper DL. 2011. A novel mechanism for glycoconjugate vaccine activation of the adaptive immune system. Nat. Med. 2011 Nov 20;17(12):1602-9.
• Webb TJ, Li X, Giuntoli RL 2nd, Lopez PH, Heuser C, Schnaar RL, Tsuji M, Kurts C, Oelke M, Schneck JP. 2012. Molecular Identification of GD3 as a Suppressor of the Innate Immune Response in Ovarian Cancer. Cancer Res. 72(15):3744-52.

BIBLIOGRAPHY - BOOKS AND OTHER MONOGRAPHS

• Tada T, Asano Y, Fujisawa I, Yagi J, Sano K, Tsuji M, Nakayama T. 1986. Adaptive construction of the immune circuit. Prog Immunol VI. 427-37.
• Tada T, Fujisawa I, Sano K, Tsuji M, Yagi J, Asano Y, Uracz W. 1986. The immune circuit: Somatic generation of epitopes involved in the mutual recognition by different subsets of T cells. In: Reichlin M, Capra JD, eds. Idiotypes. New York: Academic Press, 249-61.
• Tada T, Sano K, Tsuji M, Fujisawa I, Asano Y. 1987. Autoimmunity and immune circuit. In: Wigzell H, Kyogoku M. eds. New Horizons in Animal Models for Autoimmune Disease. New York: Academic Press, 341-347.
• Born W, Tsuji M, Cady C, Lahn M, Mukasa A, Reardon C, O’Brien R. 1998. Establishment of murine T cell lines and clones, hybridomas and transfectomas. In: Kaufman S, Kabelitz, D. eds. Methods in Microbiology. New York, Academic Press, 25: 205-35.
• Tsuji M. 2002. Assessing antigen-specific CD4+ and CD8+ T cell responses in mice after immunization with recombinant viruses. In: Malaria Methods and Protocols. Methods in Molecular Medicine. New Jersey: Humana Press Inc. Vol. 72: 361-367.
• Vasan S, Tsuji, M. 2009. Toxoplasmosis. In: Satoskar A, Simon G, Hotez P and Tsuji, M. eds. Parasitology. Landes Bioscience. ISBN: 978-1-57059-695-7.
• Kain KC, Tsuji, M. 2009. Malaria. In: Satoskar A, Simon G, Hotez P and Tsuji, M. eds. Parasitology. Landes Bioscience. ISBN: 978-1-57059-695-7.

TRANSLATION OF BOOK

• Tsuji M, Tada T. 1987. Introducing Immunology, Nankodo Co., Ltd., Tokyo. Originally edited by Staines, N., Brostoff, J.and James, K. Gower Medical Publishing Ltd., London (1985).

LIST OF CURRENT AND PAST TRAINEES

Current Trainee	Trainee Name	Role	Deg. at Entry	Training Period	Prior Institution	Research Topic	Current Position, Institution, and Support
Current	Xiangming Li	Post-doc	Ph.D.	2006-	University of Science and Technology of China	Development of a novel adjuvant for vaccine	Gates HIV vaccine, Enterprise
Current	Takayuki Shiratsuchi	Senior Research Scientist	Ph.D.	2006-	Univ. of Tokyo, Otsuka, Pharmaceutical Co.	CD1b/c-humanized mice & adenoviral anti-malaria vaccine	Gates HIV vaccine, Enterprise, Otsuka Pharmaceutical
Current	Jing Huang	Post-Doc	Ph.D.	2008-	Peking University, Albert Einstein college of Medicine	DNA-based malaria vaccine	GlaxoSmithKlein, NIH AI070258
Current	Rajakumar Mandraju	Post-Doc	Ph.D.	2009-	University of Hyderabad, India	Identification of novel human malarial antigens	NIH AI070258
Current	Urvashi Rai	Senior Research Assistant	M.S.	2009-	University of Nepal, New York University	Immunogenicity of VLP-based vaccines	NIH AI081510, NIH AI070258
Current	Jordana Reis	Post-doc	Ph.D.	2011-	Universidade Federal de Minas Gerais, Brazil	Mucosal Associated Invariant T cells (MAIT)	NIH AI081510
Current	Felipe Pereira	PhD student	M.S.	2011-	Federal University of Sao Paulo, Brazil	Discovery of malaria Ags by phage display	CAPES, Brazilian Fellowship
Past	trainees

ORAL PRESENTATIONS AT M AJOR CONFERENCES (ALL INVITED)

December 1992	XIIIth International Congress for Tropical Medicine and Malaria, Pattaya, Thailand
October 1994	VIIIth International Congress of Parasitology, Izmir, Turkey
November 1996	XIVth International Congress of Tropical Medicine and Malaria, Nagasaki, Japan
November 1996	Japanese Society of Immunology Meeting, Yokohama, Japan
May 1997	Japanese Society of Parasitology Meeting, Chiba, Japan
September 1997	1st International Society of Vaccine: Symposium on Vaccinology, Leesberg, VA
November 1997	Brazilian Society of Protozoology Meeting, Caxambu, Brazil
March 1998	1st Symposium on emerging and re-emerging infectious diseases, University of Illinois-Urbana/Champaign, IL
August 1998	IXth International Congress of Parasitology, Chiba, Japan
October 1999	Indo-US Vaccine Action Program, New Delhi, India
February 2000	4th International Conference of the Federation of African Immunological Societies, Yaounde, Cameroon
May 2000	Immunology 2000 (The American Association of Immunologists Annual Meeting), Seattle, WA
October 2001	XXVIth Meeting of the Brazilian Society of Immunology, Campos do Jordan, Brazil
November 2002	2nd International Workshop on CD1 Antigen Presentation and NK T Cells. Woods Hole, MA
January 2004	NIH CD1 Tetramer Workshop. NIH/NIAID, Bethesda, MD
February 2004	Japanese Infectious Disease Society Meeting. Okinawa, Japan
September 2004	3rd International Workshop on CD1 Antigen Presentation and NK T Cells. Heron Island, Australia,
October 2004	NIH Carbohydrate Moieties As Vaccine Candidates Workshop. NIH, Bethesda, MD.
October 2006	16th Annual Meeting of the Society of Biomedical Research, Gaithersburg, MD.
November 2006	VI Sao Paulo Research Conference. Sao Paulo, Brazil
February 2007	Albert Einstein College of Medicine Tuberculosis Research Symposium. Bronx, New York.
September 2007	NIH Carbohydrate Moieties As Vaccine Candidates Workshop. NIH, Bethesda, MD.

SEMINARS AT UNIVERSITIES OR INSTITUTES

December 1992	University of Tokyo, Tokyo, Japan
December 1992	Juntendo University School of Medicine, Tokyo, Japan
December 1992	Chiba University School of Medicine, Chiba, Japan
February 1995	Nagasaki University, Nagasaki, Japan
May 1996	University of Maryland School of Medicine, Baltimore, MD
November 1996	Jikei University School of Medicine, Tokyo, Japan
November 1996	University of Tokyo, Tokyo, Japan
November 1997	Federal University of Sao Paulo, Sao Paulo, Brazil
November 1997	University of Sao Paulo, Sao Paulo, Brazil
December 1997	Naval Medical Research Center, Rockville, MD
December 1997	Institute of Human Gene Therapy, University of Pennsylvania, Philadelphia, PA
March 1998	University of Mali School of Medicine, Bamako, Mali
July 1998	Institute of Molecular Pathology, University of Vienna, Vienna, Austria
July 1998	University of Mali School of Medicine, Bamako. Mali
November 1999	Tokyo Immunology Club meeting at Juntendo University, Tokyo, Japan
November 1999	Chiba University School of Medicine, Chiba, Japan
July 2000	Walter Reed Army Institute of Research, Silver Spring, MD
January 2001	Aaron Diamond AIDS Research Center, New York, NY
February 2001	University of Pennsylvania (Graduate School), Philadelphia, PA
May 2001	Vical Inc., San Diego, CA
May 2001	La Jolla Institute of Allergy and Immunology, La Jolla, CA
October 2001	Federal University of Sao Paulo, Sao Paulo, Brazil
October 2001	University of Sao Paulo, Sao Paulo, Brazil
January 2002	New York University School of Medicine (Clinical Pharmacology Grand Rounds)
March 2002	University of Southern California, Los Angels, CA
May 2002	Kirin Brewery Co. Ltd. Tokyo, Japan
May 2002	Tokyo University, Tokyo, Japan
May 2002	Kyushu University, Fukuoka, Japan
May 2002	Nippon Medical College, Tokyo, Japan
May 2002	Juntendo University School of Medicine, Tokyo, Japan
May 2002	Chiba University School of Medicine, Chiba, Japan
May 2002	Jikei University School of Medicine, Tokyo, Japan
September 2004	Queensland Institute of Medical Research, Brisbane, Australia
September 2004	Riken Institute of Allergy and Immunology, Kawasaki, Japan
January 2005	Ohio State University, Columbus, OH
November 2005	Enzo Biochem. New York, NY
November 2005	Indiana University School of Medicine. Indiana, IN
December 2005	Brown University, Providence, RI
March 2006	Genomic Research Center, Academia Sinica, Taipei, Taiwan
March 2006	Otsuka Pharmaceutical. Co. Ltd. Tokushima, Japan
March 2006	Hiroshima University School of Medicine, Hiroshima, Japan
May 2006	New York University School of Medicine, New York, NY
May 2006	Hunter College of CUNY. New York, NY
November 2006	University of Toronto. Toronto, ON, Canada
December 2007	University of Medicine & Dentistry of New Jersey. Newark, NJ
January 2008	McGill University Faculty of Medicine. Montreal, Quebec, Canada
November 2008	University of Virginia School of Medicine. Chariottesville, VA.
December 2008	Johns Hopkins University Bloomberg School of Public Health. Baltimore, MD.
October 2009	Cornell University Veterinary School. Ithaca, NY.
November 2009	Central Institute of Experimental Animals. Kanagawa, Japan
November 2009	University of Medicine & Dentistry of New Jersey. Newark, NJ

• Tsuji M, Romero P, Nussenzweig RS, Zavala F. 1990. CD4+ cytolytic T cell clone confers protection against murine malaria. J. Exp. Med. 172:1353-7. [view]
• Tsuji M, Mombaerts P, Lefrancois L, Nussenzweig RS, Zavala F, Tonegawa S. 1994. γ/δ Tcells contribute to immunity against the liver stages of malaria in α/β T cell-deficient mice. Proc. Natl. Acad. Sci. USA. 91: 345-9. [view]
• Tsuji M, Miyahira Y, Nussenzweig RS, Aguet M, Zavala F. 1995. Development of anti-malaria immunity in mice lacking interferon-γ receptor. J. Immunol. 154: 5338-44. [view]
• Tsuji M, Eyster C, O’Brien R, Born WK, Bapna M, Reichel M, Nussenzweig RS, Zavala F. 1996. Phenotypic and functional properties of murine γ/δ T cell clones derived from malaria immunized, αβ T cell-deficient mice. Int. Immunol. 8: 359-66. [view]
• Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M. 1997. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J. Immunol. 158: 1268-74. [view]
• Tsuji M, Bergmann CC, Takita-Sonoda Y, Murata, K, Rodrigues EG, Nussenzweig RS, Zavala F. 1998. Recombinant Sindbis viruses expressing a cytotoxic T lymphocyte epitope of a malaria parasite or of an influenza virus elicit protection against the corresponding pathogen in mice. J. Virol. 72: 6907-10. [view]
• Rodrigues EG, Zavala F, Nussenzweig RS, Wilson JM, Tsuji M. 1998. Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 16: 1812-17. [view]
• Fernandez JA, Zavala F, Tsuji M. 1999. Phenotypic and functional characterization of CD8+ T cell clones specific for a mouse cytomegalovirus epitope. Virology 155: 40-49. [view]
• Rodrigues EG, Claassen J, Lee S, Wilson JM, Nussenzweig RS, Tsuji M. 2000. Interferon-gamma Independent CD8+ T cell-mediated protective anti-malaria immunity induced by recombinant adenovirus. Parasite Immunol. 22: 157-160. [view]
• Molano A, Chiu Y-H, Nosseir S, Bendelac A, Tsuji M. 2000. Cutting Edge: The IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: Exploring the role of GPIs in NKT cell activation and antimalarial responses. J. Immunol. 164: 5005-5009. [view]
• Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, Bruna-Romero O, Nakayama T, Taniguchi M, Bendelac A, Van Kaer L, Koezuka Y, Tsuji M. 2000. α-GalCer-activated Vα14 natural killer T cells mediate protection against murine malaria. Proc. Natl. Acad. Sci. USA. 97: 8461-8466. [view]
• Pasquetto V, Guidotti LG, Kakimi K, Tsuji M, Chisari FV. 2000. Host-virus interactions during malaria infection in hepatitis B virus transgenic mice. J. Exp. Med. 192: 529-536. [view]
• Fernandez JA, Rodrigues EG, Tsuji M. 2000. Multifactorial protective mechanisms to limit viral replication in the lung of mice during primary murine cytomegalovirus infection. Viral. Immunol. 13: 287-295. [view]
• Tsuji M, Rodrigues EG, Nussenzweig RS. 2001. Progress towards a malaria vaccine: Efficient induction of anti-malaria immunity. Biol. Chemistry 382: 553-570. Review. [view]
• Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla JC, Tsuji M. Nussenzweig RS. 2001. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. USA. 98: 11491-11496. [view]
• Tsuji M, Zavala F. 2001. Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites. Mol. Immunol. 38; 433-442. Review. [view]
• Gonzalez-Aseguinolaza G, Van Kear L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M. 2002. The natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195: 617-624. [view]
• Tsuji M, Zavala F. 2003. T cells as mediators of protective immunity against malaria liver stages. Trends in Parasitol. 19: 88-93. Review. [view]
• Bruna-Romero O, Schmieg J, Del Val M, Buschle M, Tsuji M. 2003. The dendritic cell-specific chemokine DC-CK1 enhances protective cell-mediated immunity to murine malaria. J. Immunol. 170: 3195-3203. [view]
• Schmieg J, Gonzalez-Aseguinolaza G, Tsuji M. 2003. The role of natural killer T cells and other T cell subsets against infection by liver stages of malaria parasites. Microbes and Inf. 5: 499-506. Review. [view]
• Schmieg J, Yang G, Franck RW, Tsuji M. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 198: 1631-1641. [view]
• Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT. 2004. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine 22: 3575-3584. [view]
• Schmieg J, Yang G, Franck RW, Van Rooijen N, Tsuji M. 2005. Glycolipid-presentation to natural killer T cells differs in an organ-dependent fashion. Proc. Natl. Acad. Sci. USA. 102: 1127-1132. [view]
• Kinjo Y, Wu D, Kim G, Xing G-w, Poles MA, Ho DD, Tsuji M, Kawahara K, Wong C-H, Kronenberg M. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520 - 525. [view]
• Kennan RP, Machado FS, Lee SC, Desruisseaux MS, Wittner M, Tsuji M, Tanowitz, HB. 2005. Reduced cerebral blood flow and N-acetyl aspartate in a murine model of cerebral malaria. Parasitol. Res. 96: 302 - 307. [view]
• Ophorst OJAE, Radosevic K, Havenga MJE, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M. 2006. Recombinant human adenovirus serotype 35-based malaria vaccine: Immunogenicity and protection against Plasmodium yoelii in mice. Infect. Immun. 74: 313-320. [view]
• Machado F, Desruisseau MS, Nagajyoshi, Kennan RP, Hetherington HP, Wittner M, Weiss LM, Lee SC, Scherer PE, Tsuji M, Tanowitz HB. 2006. Endothelin in a Murine Model of Cerebral Malaria. Exp. Biol. Med. 231: 1176-1181. [view]
• Fujio M, Wu D, Garcia-Navarro R, Ho D.D, Tsuji M, Wong C-H. 2006. Structure-Based Discovery of Glycolipids for CD1d-mediated NKT cell activation: Tuning the Adjuvant versus Immunosuppression Activity. J. Am. Chem. Soc. 128: 9022-9023. [view]
• Tsuji M. 2006. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell. Mol. Life Sci. 63:1889-1898. Review. [view]
• Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Franck RW, Tsuji M, Steinman RM. 2006. The glycolipid α-C-GalCer is a distinct inducer of dendritic cell maturation and both innate and adaptive T cell immunity in mice. Proc.Natl.Acad.Sci. USA. 103:11252-11257. [view]
• Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia M, Zajonc DM, Ben-Menachem G, Ainge GD, Painter GF, Khurana A, Hoebe K, Behar SM, Beutler B, Wilson IA, Tsuji M, Sellati TJ, Wong C-H, Kronenberg M. 2006. NKT cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7: 978-986. [view]
• Franck RW, Tsuji M. 2006. α-C-Galactosylceramides: Synthesis and Immunology. Acc. Chem. Res. 39: 692-701. Review. [view]
• Vasan S, Poles MA, Horowitz A, Siladji EE, Markowitz M, Tsuji M. 2007. Percentage and function of NKT cells, a potential anti-HIV effector cell, are preserved by beginning HAART during acute and early HIV-1 Infection. Int. Immunol. 19: 943-951. [view]
• Huang Y, Chen A, Chen Z, Zhang W, Song Y, Gurner D, Gardiner D, Basu S, Ho DD, Tsuji M. 2008. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand α-galactosylceramide. Vaccine, 28;26(15):1807-16 [view]
• Desruisseaux MS, Gulinello M, Smith DN, Lee SC, Tsuji M, Weiss LM, Spray DC, Tanowitz HB. 2008. Cognitive dysfunction in mice infected with Plasmodium berghei strain ANKA. J Infect Dis. 2008 Jun 1;197(11):1621-7. [view]
• Liang PH, Imamura M, Li X, Wu D, Fujio M, Guy RT, Wu BC, Tsuji M, Wong CH. 2008. Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production. J Am Chem Soc. 2008 Sep 17;130(37):12348-54. [view]
• Grajewski RS, Agarwal RK, Kronenberg M, Sidobre S, Su SB, Silver PB, Tsuji M, Franck RW, Lawton AP, Chan C-C, Caspi RR. 2008. Activation of iNKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-γ production and dampening of the adaptive Th1 and Th17 responses. J Immunol. 2008 Oct 1;181(7):4791-7. [view]
• Shiratsuchi T, Schneck J, Kawamura A, Tsuji M. 2009. Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J Immunol Methods. 30;345(1-2):49-59. [view]
• Li X, Chen G, Garcia-Navarro R, Franck RW, Tsuji M. 2009. Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells. Immunology. 127(2):216-225. [view]
• Kopecky-Bromberg SA, Fraser KA, Pica N, Carnero E, Moran TM, Franck RW, Tsuji M, Palese P. 2009. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine. 2009 Jun 8;27(28):3766-74.[view]
• Li X, Shiratsuchi T, Chen G, Dellabona P, Casorati G, Franck RW, Tsuji M. 2009. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells. J Immunol. 183(7):4415-21. [view]
• Horowitz A, Li X, Poles MA, Tsuji M. 2009. Use of immobilized HLA-A2:Ig dimeric proteins to determine the level of epitope-specific, HLA-restricted CD8(+) T-cell response. Scand J Immunol. 70(5):415-22. [view]
• Schmieg J, Yang G, Franck RW, Tsuji M. 2010. A multifactorial mechanism in the superior anti-malarial activity of a-C-GalCar J. Biomed Biotech. 2010:283612. [view]
• Vasan S, Tsuji M. 2009. Friend-Foe & Predator-Prey Relationship: the role of NKT cells in Malaria and HIV infection and immunity. sminar Immunol, invited Review.
• Tsuji M. 2009. Re-evaluating the role of T cells for the development of T cell-based malaria vaccine. Exp. Parasitol. Invited Review.
• Shiratsuchi T, Kraus A, Worgall S, Tsuji M. 2010. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest. 2010 Oct;120(10):3688-701. [view]
• Li X, Fujio M, Imamura M, Wu D, Vasan S, Wong CH, Ho DD, Tsuji M. 2010. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci. 107(29):13010-5. [view]
• Li X, Shiratsuchi T, Chen G, Franck RW, Tsuji M. 2009. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine iNKT cells. J. Immunol. 183: 4415-4421. [view]
• Horowitz A, Li X, Poles MA, Tsuji M. 2009. Quantifying cytokine production by epitope-specific, HLA-restricted CD8+ T cells after stimulation by immobilized HLA-A2:Ig dimeric proteins. Scan. J. Immunol. 70: 415-422. [view]
• Sullivan BA, Nagarajan NA, Wingender G, Wang J, Scott I, Tsuji M. Franck RW, Porcelli SA, Zajonc DM, Kronenberg M. 2010. Mechanisms for Glycolipid Antigen-Driven Cytokine Polarization by V{alpha}14i NKT Cells. J. Immunol. 184: 141-153. [view]
• Vasan S, Tsuji M. 2010. A double-edged sword: The Role of NKT cells in Malaria and HIV Infection and Immunity. Seminar Immunol. Review. 22: 87-96. [view]
• Schmieg J, Yang G, Franck RW, Tsuji M. 2010. A multifactorial mechanism in the superior anti-malarial activity of a-C-GalCer. J. Biomed. Biotech. 2010: 283612: 1-11. [view]
• Lombardi V, Stock P, Singh AK, Kerzerho J, Yang W, Sullivan BA, Li X, Shiratsuchi T, Hnatiuk NE, Howell AR, Yu KO, Porcelli SA, Tsuji M, Kronenberg M, Wilson SB, Akbari O. 2010. A CD1d-dependent antagonist inhibits the activation of iNKT cells and prevents development of allergen-induced airway hyperreactivity. J. Immunol. 184: 2107-15. [view]
• Tsuji M. 2010. Re-evaluating the role of T cells for the development of T cell-based, malaria vaccine. Exp. Parasitol. Review.
• Li X, Fujio M, Imamura M, Wu D, Vasan S, Wong CH, Ho DD, Tsuji M. 2010. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci, 20;107(29):13010-5. [view]
• Shiratsuchi T, Rai U, Kraus A, Worgall S, Tsuji M. 2010. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents pre-existing immunity to adenovirus in mice. J. Clin. Invest. 120(10):3688-701. [view]
• Renukaradhya GJ, Manickam C, Khatri M, Rauf A, Li X, Tsuji M. Rajashekara G, Dwivedi V. 2010. Functional Invariant NKT Cells in Pig Lungs Regulate the Airway Hyperreactivity: A Potential Animal Model. J. Clin Immunol. 31(2):228-39. [view]
• Padte NN, Li X, Tsuji M, Vasan S. 2010. Clinical Development of a Novel CD1d-binding NKT Cell Ligand as a Vaccine Adjuvant. Clin Immunol. 140(2):142-51. [view]
• Mishra S, Rai U, Shiratsuchi T, Li X, Vanloubbeeck Y, Cohen J, Nussenzweig RS, Winzeler EA, Tsuji M, Nussenzweig V. 2011. Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites. Vaccine. 29(43):7335-42. [view]
• Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, Li Y, Imamura M, Kaneko Y, Okawara A, Miyazaki Y, Gómez-Velasco A, Rogers P, Dahesh S, Uchiyama S, Khurana A, Kawahara K, Yesilkaya H, Andrew PW, Wong CH, Kawakami K, Nizet V, Besra GS,Tsuji M, Zajonc DM, Kronenberg M. 2011. Invariant NKT cells recognize glycolipids from pathogenic gram-positive bacteria. Nat Immunol. 2011 Sep 4;12(10):966-74. [view]
• Avci FY, Li X, Tsuji M, Kasper DL. 2011. A novel mechanism for glycoconjugate vaccine activation of the adaptive immune system. Nat. Med. 2011 Nov 20;17(12):1602-9. [view]
• Webb TJ, Li X, Giuntoli RL 2nd, Lopez PH, Heuser C, Schnaar RL, Tsuji M, Kurts C, Oelke M, Schneck JP. 2012. Molecular Identification of GD3 as a Suppressor of the Innate Immune Response in Ovarian Cancer. Cancer Res. 72(15):3744-52. [view]

---

Moriya Tsuji	Associate Professor
Ryota Funakoshi	Visiting Intern
Jing Huang	Post Doctoral Fellow
Xiangming Li	Research Scientist
Tiffany Tsao	Research Technician